<DOC>
	<DOC>NCT02692599</DOC>
	<brief_summary>The purpose of this study is to evaluate the immunogenicity and safety of a live attenuated mumps vaccine in healthy infants between 8 - 18 months old with a commercialized live attenuated mumps vaccine as the control vaccine.</brief_summary>
	<brief_title>Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants</brief_title>
	<detailed_description>This study is a randomized, blind, single-center, controlled phase III clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of a live attenuated mumps vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. The control vaccine is a commercialized live attenuated mumps vaccine manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd. All participants are healthy infants between 8 - 18 months old, and will be randomly assigned into experimental group or control group in the ratio 1:1.</detailed_description>
	<mesh_term>Mumps</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy volunteer between 8 18 months old; Proven legal identity; Guardian(s) of the volunteer should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study; Complying with the requirement of the study protocol; Axillaty temperature &gt; 37.0 Â°C; Any significant abnormity of heart, lung, liver, spleen, lymph nodes, or pharynx; Acute disease or acute stage of chronic disease within 7 days prior to study entry; Prior vaccination with mumps vaccine or with history of mumps infection; History of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) about vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc; Receipt of any of the following products: 1. Any subunit vaccine or inactivated vaccine within 14 days prior to study entry; 2. Any live attenuated vaccine within 28 days prior to study entry; 3. Any other investigational medicine(s) within 30 days prior to study entry; 4. Blood product (e.g., immunoglobulin) within 3 months prior to study entry; 5. Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute noncomplicated dermatitis) within 6 month prior to study entry; Epilepsy (except febrile seizures), history of seizures or convulsions, or a family history of mental illness; Autoimmune disease or immunodeficiency; Congenital malformation, developmental disorders, or serious chronic diseases (such as Down's syndrome, diabetes, sickle cell anemia or neurological disorders; Severe malnutrition; Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities); Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators; Participants with the following conditions between day 0 28 of this study would be included in the full analysis set (FAS), but would be excluded from the per protocol set (PPS): 1. Receipt of any other investigational or unregistered product (drug or vaccine); 2. Receipt of immunosuppressant (corticosteroid dosage that equivalent to or above 0.5 mg prednisone/kg weight/day) for &gt; 14 days consecutively, except for inhalant or locally administrated corticosteroid; 3. Receipt of immunoglobulin and/or blood product; 4. Newly diagnosed autoimmune disease or immunodeficiency (e.g., HIV infection);</criteria>
	<gender>All</gender>
	<minimum_age>8 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>live attenuated mumps vaccine</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>infant</keyword>
</DOC>